A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK 05/014, ISRCTN53643604).

被引：1
|
作者：
Huddart, R. A.
Gabe, R.
Cafferty, F.
Pollock, P.
White, J. D.
Shamash, J.
Stenning, S. P.
机构：
[1] Inst Canc Res, Sutton, Surrey, England
[2] Med Res Council Clin Trials Unit, London, England
[3] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[4] St Bartholomews Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4508
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4508
引用
收藏
页数：1
相关论文
共 22 条
  • [1] A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)
    Huddart, Robert A.
    Gabe, Rhian
    Cafferty, Fay H.
    Pollock, Philip
    White, Jeff D.
    Shamash, Jonathan
    Cullen, Michael H.
    Stenning, Sally P.
    EUROPEAN UROLOGY, 2015, 67 (03) : 534 - 543
  • [2] Toxicity and Use of Granulocyte Colony-stimulating Factor Prophylaxis in a Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor Prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN53643604)
    Huddart, R. A.
    Gabe, R.
    Stenning, S. P.
    Pollock, P.
    White, J. D.
    Cafferty, F. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S517 - S517
  • [3] Long term follow-up of the MRC TE23 randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) in poor prognosis germ cell tumours (GCT) (CRUK/05/014; ISRCTN53643604)
    Huddart, R. A.
    Cafferty, F.
    White, J.
    Shamash, J.
    Hennig, I. M.
    Cullen, M.
    Stenning, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors
    Christian, JA
    Huddart, RA
    Norman, A
    Mason, M
    Fossa, S
    Aass, N
    Nicholl, EJ
    Dearnaley, DP
    Horwich, A
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 871 - 877
  • [5] Paclitaxel plus BEP (T-BEP) Regimen as Induction Chemotherapy in Poor Prognosis Patients With Nonseminomatous Germ Cell Tumors: A Phase II Study
    Tryakin, A.
    Fedyanin, M.
    Kanagavel, D.
    Fainstein, I.
    Sergeev, J.
    Polockij, B.
    Matveev, V.
    Zakharova, T.
    Garin, A.
    Tjulandin, S.
    UROLOGY, 2011, 78 (03) : 620 - 625
  • [6] Paclitaxel plus BEP (T-BEP) regimen as induction chemotherapy (CT) in nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis; A phase II study.
    Tryakin, A.
    Fedyanin, M.
    Sergeev, U.
    Pokataev, I.
    Ahmedov, B.
    Zakharova, T.
    Mitin, A.
    Fainstein, I.
    Garin, A.
    Tjulandin, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)
    Cafferty, Fay H.
    White, Jeff D.
    Shamash, Jonathan
    Hennig, Ivo
    Stenning, Sally P.
    Huddart, Robert A.
    EUROPEAN JOURNAL OF CANCER, 2020, 127 : 139 - 149
  • [8] Phase II trial of dose-dense BEP for intermediate- and poor-prognosis metastatic germ cell tumors.
    Rimmer, Y. L.
    Chester, J. D.
    Stark, D. P.
    Joffe, J. K.
    Shamash, J.
    White, J. D.
    Upton, N.
    Wason, J.
    Parashar, D.
    Williams, M. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Efficacy results of phase II trial
    Tryakin, Alexey
    Fedyanin, Mikhail
    Sergeev, Urii
    Bulanov, Anatoly
    Ahmedov, Bahrom
    Zakharova, Tatiana
    Mitin, Andrey
    Fainstein, Igor
    Garin, Avgust
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Dose-dense BEP (ddBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Safety results of phase II trial
    Tryakin, Alexey
    Fedyanin, Mikhail
    Sergeev, Urii
    Bulanov, Anatoly
    Ahmedov, Bahrom
    Zakharova, Tatiana
    Mitin, Andrey
    Feinstein, Igor
    Garin, August
    Tjuiandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
123